尚无定论？ACE抑制剂和ARB在冠状动脉结局方面的类别特异性差异：来自荟萃分析和降压治疗试验协作组的见解。 - Suppr

Suppr

超能文献

Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration.

作者信息

Strauss Martin H, Lonn Eva M, Verma Subodh

出版信息

Eur Heart J. 2005 Nov;26(22):2351-3. doi: 10.1093/eurheartj/ehi574. Epub 2005 Oct 11.

DOI:10.1093/eurheartj/ehi574

PMID:16219656

Abstract

摘要

相似文献

Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration.尚无定论？ACE抑制剂和ARB在冠状动脉结局方面的类别特异性差异：来自荟萃分析和降压治疗试验协作组的见解。

Eur Heart J. 2005 Nov;26(22):2351-3. doi: 10.1093/eurheartj/ehi574. Epub 2005 Oct 11.

Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂在心肌梗死、中风和死亡风险方面的比较：一项荟萃分析。

J Hypertens. 2008 Jul;26(7):1282-9. doi: 10.1097/HJH.0b013e328306ebe2.

Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?肾素-血管紧张素系统抑制对靶器官保护的作用：我们能否做得更好？

Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019.

Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.血管紧张素II受体阻滞剂与心肌梗死：随机临床试验的最新分析

J Hypertens. 2009 May;27(5):941-6. doi: 10.1097/HJH.0b013e32832961ed.

ACE inhibitors and ARBs: antihypertensive medications in CKD.

Nephrol Nurs J. 2005 May-Jun;32(3):332-3.

ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.

Arch Intern Med. 2009 Oct 26;169(19):1810; author reply 1810-1. doi: 10.1001/archinternmed.2009.371.

Blood pressure drugs compared. ACE inhibitors beat ARBs hands-down for survival benefit.血压药物对比。就生存获益而言，血管紧张素转换酶抑制剂完胜血管紧张素Ⅱ受体拮抗剂。

Harv Heart Lett. 2012 Jun;22(10):5.

Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.血管紧张素II受体拮抗剂与心力衰竭：血管紧张素转换酶抑制剂仍是一线选择。

Prescrire Int. 2005 Oct;14(79):180-6.

Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients.血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂在高血压患者心肌梗死一级预防中的比较。

Am J Cardiol. 2004 Aug 15;94(4):479-81. doi: 10.1016/j.amjcard.2004.04.063.

Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?抑制肾素-血管紧张素系统以预防心血管疾病：我们是否需要更全面的策略？

Rev Cardiovasc Med. 2006 Spring;7(2):45-54.

引用本文的文献

Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.固定剂量复方制剂在高血压治疗中的应用依据：乐卡地平/依那普利的疗效和耐受性。

Clin Drug Investig. 2010;30(12):843-54. doi: 10.1007/BF03256912.

Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.联合治疗用于动脉粥样硬化的治疗或预防：重点关注脂质-肾素-血管紧张素系统的相互作用。

Atherosclerosis. 2010 Apr;209(2):307-13. doi: 10.1016/j.atherosclerosis.2009.09.007. Epub 2009 Sep 12.

Perindopril versus angiotensin II receptor blockade in hypertension and coronary artery disease: implications of clinical trials.

Clin Drug Investig. 2007;27(3):149-61. doi: 10.2165/00044011-200727030-00001.

Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.培哚普利：对其在冠心病患者或有患冠心病风险的患者中的应用综述。

Drugs. 2006;66(2):235-55. doi: 10.2165/00003495-200666020-00010.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验